


# CALL FOR APPLICATIONS

## Medical Doctoral (MD) student positions available

### Overview




Our research programme aims to explore novel approaches for antiviral chemotherapy and immune intervention that build upon recent developments in molecular virology and immunology. The individual research projects address **antiviral small molecules (area A)**, **immune cell-mediated antiviral effects (area B)**, and **antibody-based approaches (area C)**. Altogether, we envision multimodal antiviral strategies that combine antiviral chemotherapy with immune-based interventions as the most promising path towards the control of persistent viruses.

### Projects with open positions

(printed in bold)

Area A: Antiviral small molecules		
A1	Manfred Marschall	CDK7 kinase pathways as a drug targeting strategy for broad antiherspesviral intervention
A2	Andrea Thoma-Kreß	Enhancing immunogenicity of Human T-cell leukaemia virus Type 1 (HTLV-1) by interfering with viral transcription
A3	Thomas Gramberg	Enhancing antiviral immunity by blocking SAMHD1 activity
A4	Ulrich Schubert & Vladimir Temchura	Antiretroviral therapy with amendment of HIV-1-specific T-cell response
Area B: Harnessing T-cell immunity		
B1	Ilka Knippertz	Transcriptional targeting of dendritic cells as a new therapeutic vaccine against HIV-1
B2	Diana Dudziak & Christian Lehmann	LCMV as model for immune intervention by antigen targeting in chronic viral infections
B3	Thomas Harrer & C. Krystelle Nganou-Makamdop	Induction of Nef-resistant HIV-1-specific CTL responses as a new strategy for the development of HIV-1-specific therapeutic vaccines
B4	Jan Dörrie	Preclinical evaluation of a combination of checkpoint blockade with dendritic cell vaccination against Merkel Cell Carcinoma and other virally induced cancers
B5	<b>Matthias Tenbusch</b>	<b>Induction of tissue-resident memory T cells by gene-based vaccines as first line of defence against pathogens entering the host via mucosal surfaces</b>
B6	Armin Essner	An animal model of HLA-independent, chimeric antigen receptor-mediated adoptive immunotherapy against cytomegaloviruses
B7	Anita Kremer & Michael Wiesener	CMV-specific T cells for prevention and therapy of CMV reactivation in patients after kidney transplantation
Area C: Antibody-based immunotherapy and prophylaxis		
C1	Jutta Eichler	Towards novel HIV immunotherapeutics: bispecific antibody paratope mimics
C2	Heinrich Sticht	Structure-based design and optimisation of ligands for novel antiviral strategies
C3	Thomas Winkler & Marco Thomas	Protection from cytomegalovirus infection by antibodies
C4	<b>Frank Neipel &amp; Hans-Martin Jäck</b>	<b>Recombinant MHV-68 as a model system for Kaposi's sarcoma-associated herpesvirus vaccine development</b>
C5	Klaus Überla & Anja Lux	Inducing long-lasting HIV Env-specific antibody responses by intrastructural help

### Training programme



Applications: [www.virologie.uk-erlangen.de/en/GRK2504/](http://www.virologie.uk-erlangen.de/en/GRK2504/)

If you are interested to apply, please contact one of the project leaders that offer a MD project (see [www.virologie.uk-erlangen.de/en/GRK2504/](http://www.virologie.uk-erlangen.de/en/GRK2504/)) and submit your application as indicated on our webpage until **November 27<sup>th</sup>, 2020** to [grk2504-info@fau.de](mailto:grk2504-info@fau.de)

Eligible candidates will be invited to present themselves, their motivation to join the GRK and their motivation to select the particular project(s) in a 5 minute oral presentation (in English) via zoom, on **December 09<sup>th</sup>, 2020**.